MET in gastric cancer - discarding a 10% cutoff rule

Histopathology

Volumn 68, Issue 2, 2016, Pages 241-253

  Metzger, Marie Luise ^a   Behrens, Hans Michael ^a   Böger, Christine ^a   Haag, Jochen ^a   Krüger, Sandra ^a   Röcken, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

MET; Gastric cancer; Immunohistochemistry; in situ hybridization; Predictive biomarker; Targeted therapy

Indexed keywords

BIOLOGICAL MARKER; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; SCATTER FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MET PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHROMOGENIC IN SITU HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MICROSCOPY; MOLECULAR PATHOLOGY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER; TUMOR CELL; COHORT ANALYSIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PROGNOSIS; STOMACH TUMOR;

AGED; BIOMARKERS, TUMOR; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84954510133     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12745     Document Type: Article

References (43)

1. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann.Oncol. 2003; 14(Suppl 2); ii31-ii36.
2. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006; 355; 11-20.
3. Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303; 1729-1737.
4. Hack SP, Bruey JM, Koeppen H. HGF/MET directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014; 5; 2866-2880.
5. Jardim DL, de Melo Gagliato D, Falchook GS et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a Phase I unit. Oncotarget 2014; 5; 1837-1845.
6. Kang YK, Muro K, Ryu MH et al. A Phase II trial of a selective c-MET inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest. New Drugs 2014; 32; 355-361.
7. Lennerz JK, Kwak EL, Ackerman A et al. Met amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 2011; 29; 4803-4810.
8. Shah MA, Wainberg ZA, Catenacci DV et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), CMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE 2013; 8; e54014.
9. Teng L, Lu J. CMET as a potential therapeutic target in gastric cancer (review). Int. J. Mol. Med. 2013; 32; 1247-1254.
10. Bang YJ, Van CE, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (Toga): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376; 687-697.
11. Lauren T. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 1965; 64; 31-49.
12. Namikawa T, Hanazaki K. Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma. World J. Gastroenterol. 2010; 16; 4634-4639.
13. Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. Chichester: Wiley-Blackwell, 2009.
14. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 1985; 109; 716-721.
15. Warneke V, Behrens HM, Haag J et al. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn. Mol. Pathol. 2013; 22; 127-137.
16. Behrens HM, Warneke VS, Böger C et al. Reproducibility of HER2/neu scoring in gastric cancer and assessment of the 10% cut-off rule. Cancer Med. 2015; 4; 235-244.
17. Graveel CR, Tolbert D, Vande Woude GF. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb. Perspect. Biol. 2013; 5; a009209.
18. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012; 61; 673-684.
19. Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in gastric cancer. World J. Gastroenterol. 2014; 20; 4536-4545.
20. Betts G, Valentine H, Pritchard S et al. FGFR2, HER2 and CMET in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virchows Arch. 2014; 464; 145-156.
21. Fuse N, Kuboki Y, Kuwata T et al. Prognostic impact of HER2, EGFR, and C-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer 2015; doi:10.1007/s10120-015-0471-6.
22. Guo T, Yang J, Yao J, Zhang Y, Da M, Duan Y. Expression of MACC1 and c-MET in human gastric cancer and its clinical significance. Cancer Cell Int. 2013; 13; 121.
23. Ha SY, Lee J, Kang SY et al. Met overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod. Pathol. 2013; 26; 1632-1641.
24. Ha SY, Lee J, Jang J et al. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int. J. Cancer 2015; 136; 1629-1635.
25. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-MET protooncogene in human gastric carcinoma - correlation to clinical features. Acta Oncol. 2001; 40; 638-643.
26. Kubicka S, Claas C, Staab S et al. P53 mutation pattern and expression of c-ERBB2 and c-MET in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig. Dis. Sci. 2002; 47; 114-121.
27. Kurokawa Y, Matsuura N, Kawabata R et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann. Surg. Oncol. 2014; 21(Suppl 4); 584-590.
28. Lee HE, Kim MA, Lee HS et al. Met in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br. J. Cancer 2012; 107; 325-333.
29. Li Y, Chen CQ, He YL et al. Abnormal expression of e-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J. Surg. Oncol. 2012; 106; 304-310.
30. Liu YJ, Shen D, Yin X et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br. J. Cancer 2014; 110; 1169-1178.
31. Nagatsuma AK, Aizawa M, Kuwata T et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 2015; 18; 227-238.
32. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-MET and c-ERB B-2 in human gastric carcinomas. Cancer 1999; 85; 1894-1902.
33. Taniguchi K, Yonemura Y, Nojima N et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-MET), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 1998; 82; 2112-2122.
34. Toiyama Y, Yasuda H, Saigusa S et al. Co-expression of hepatocyte growth factor and c-MET predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-MET signaling in gastric cancer. Int. J. Cancer 2012; 130; 2912-2921.
35. Wu JG, Yu JW, Wu HB et al. Expressions and clinical significances of c-MET, p-MET and E2F-1 in human gastric carcinoma. BMC Res Notes 2014; 7; 6.
36. Drebber U, Baldus SE, Nolden B et al. The overexpression of c-MET as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol. Rep. 2008; 19; 1477-1483.
37. Graziano F, Galluccio N, Lorenzini P et al. Genetic activation of the met pathway and prognosis of patients with high-risk, radically resected gastric cancer. J. Clin. Oncol. 2011; 29; 4789-4795.
38. Lee J, Seo JW, Jun HJ et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol. Rep. 2011; 25; 1517-1524.
39. Catenacci DV, Cervantes G, Yala S et al. Ron (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol. Ther. 2011; 12; 9-46.
40. Warneke VS, Behrens HM, Boger C et al. HER2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann. Oncol. 2013; 24; 725-733.
41. Watson S, Validire P, Cervera P et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann. Oncol. 2013; 24; 3035-3039.
42. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513; 202-209.
43. Wang K, Yuen ST, Xu J et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 2014; 46; 573-582.